VIP Benefits: Claims vs What Studies Show
Benefits people claim for VIP, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 10 / 0
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- compounded or research
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Immune system | Human RCT evidence, 4 of 4 | 4 / 0 | Time to discharge; Day-90 ordinal outcome; Mortality to day 90 | Evidence for immune system |
| Heart health | Human RCT evidence, 4 of 4 | 3 / 0 | Airway function and cardiovascular effect; Pulmonary vasodilation; Blood pressure and vasodilation | Evidence for heart health |
| Erectile dysfunction | Human observational evidence, 3 of 4 | 1 / 0 | Efficacy (resumption of penetrative sexual activity); Intracavernosal VIP plus phentolamine for ED | None |
| Inflammation | Human observational evidence, 3 of 4 | 2 / 0 | Symptom reversal after multi-part treatment; TNF-alpha production and regulatory T cells | Evidence for inflammation |
| Energy | Human observational evidence, 3 of 4 | 1 / 0 | Symptom reversal after multi-part treatment | Evidence for energy |
| Gut health | Human observational evidence, 3 of 4 | 1 / 0 | Symptom reversal after multi-part treatment | Evidence for gut health |
Strongest study per claim: Immune system, Medical principles and practice 2025, PMID 39870064; Heart health, Thorax 1986, PMID 3787552; Erectile dysfunction, The journal of sexual medicine 2025, PMID 40192471.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Time to discharge | Average time to discharge was 7.8 days on inhaled aviptadil versus 10 days on placebo (p = 0.049). | Human RCTn = 80 | Medical principles and practice 2025, PMID 39870064 |
| Day-90 ordinal outcome | Aviptadil did not significantly improve the day-90 outcome category. | Human RCTn = 461 | The Lancet. Respiratory medicine 2023, PMID 37348524 |
| Mortality to day 90 | Day-90 mortality was 38% on aviptadil and 36% on placebo with no significant difference. | Human RCTn = 461 | The Lancet. Respiratory medicine 2023, PMID 37348524 |
| Primary endpoint (alive and free of respiratory failure at day 60) | The primary endpoint was not met (OR 1.6, 95% CI 0.86-3.11). | Human RCTn = 196 | Critical care medicine 2022, PMID 36044317 |
| 60-day survival (secondary) | A secondary survival analysis showed two-fold odds of survival (OR 2.0, p = 0.035). | Human RCTn = 196 | Critical care medicine 2022, PMID 36044317 |
| Airway function and cardiovascular effect | At 6 pmol/kg/min infused VIP lowered systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min, with no change in airway conductance. | Human controlled trial | Thorax 1986, PMID 3787552 |
| Efficacy (resumption of penetrative sexual activity) | About 59% found the aviptadil plus phentolamine injection effective, in a retrospective non-controlled series; the formulation is not VIP alone. | Human observationaln = 308 | The journal of sexual medicine 2025, PMID 40192471 |
| Oxygenation | Mean oxygen saturation rose from 87.86% to 93.43% after 3 days of infusion, in a small uncontrolled series. | Human observationaln = 6 | Indian journal of critical care medicine 2024, PMID 38510776 |
| Symptom reversal after multi-part treatment | Symptoms resolved after removal of biotoxin exposure plus VIP replacement, dental extractions and a relaxation program; the effect of VIP alone cannot be separated. | Human case reportn = 1 | The American journal of case reports 2016, PMID 27165859 |
| TNF-alpha production and regulatory T cells | Nebulized VIP was well tolerated and reduced TNF-alpha production by lung lavage cells in sarcoidosis. | Human uncontrolled trialn = 20 | American journal of respiratory and critical care medicine 2010, PMID 20442436 |
| Pulmonary vasodilation | A single inhaled aviptadil dose had a modest, short-lived vasodilating effect with no side effects reported. | Human uncontrolled trialn = 20 | The European respiratory journal 2008, PMID 18978135 |
| Blood pressure and vasodilation | VIP infusion caused sustained vasodilatation and lowered total peripheral resistance by 30% and mean arterial pressure by 12%. | Human uncontrolled trialn = 6 | The American journal of cardiology 1987, PMID 3687785 |
| Survival odds vs placebo | The two RCTs together showed no survival benefit (OR 1.01, p = 0.93). | Meta-analysisn = 665 | Indian journal of critical care medicine 2025, PMID 41368449 |
| Intracavernosal VIP plus phentolamine for ED | The review reports effectiveness in at least 80% of men with ED in clinical studies; this is a company-product review, not primary data. | Review | BJU international 2008, PMID 18485029 |
Claimed: help for lung inflammation and COVID
In the large US trial of intravenous aviptadil in COVID-19 respiratory failure, the odds of a better day-90 outcome category were 1.11 versus placebo, a non-significant result (p=0.54).[2]
A smaller trial missed its primary endpoint but reported a secondary survival signal, with odds of improved survival at 60 days of 2.0 (p = 0.035).[3]
An 80-patient trial of inhaled aviptadil reported average time to discharge of 7.8 days versus 10 days with placebo (p = 0.049).[1]
A meta-analysis of the two randomized trials found a survival odds ratio of 1.01 versus placebo, which indicates no significant benefit.[11]
Claimed: better sexual function
In a retrospective review of men with refractory erectile dysfunction, 182 men (59%) found an aviptadil plus phentolamine injection into the penis effective; this was not a controlled trial and not subcutaneous or nasal VIP.[5]
Claimed: calming inflammation and gut problems
In sarcoidosis patients, inhaled VIP was safe, well tolerated and reduced the production of tumor necrosis factor-alpha by lung lavage cells, in an uncontrolled study.[8]
For the gut claim, the only record is a single case report in which symptoms resolved after removing mould exposure, VIP replacement, dental extractions and a relaxation programme together, so VIP's own effect cannot be separated.[7]
Heart effects seen in people
In healthy volunteers, infused VIP at 6 pmol/kg/min lowered mean systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min; that is a vasodilator effect, not a benefit.[4]
No study for energy
The evidence file lists no human study of VIP or aviptadil for energy or fatigue other than the single multi-part case report, so an energy benefit is unsupported by trial data here.
Calculated from evidence file web/src/data/evidence/vip.json; energy trials 0; case reports 1. Formula: energy trials = 0; case reports = 1 and it combined four interventions
More on VIP
Common questions
Is VIP proven to work?
The strongest study we summarise for VIP is human rct evidence, among 12 studies. A trial result is not an approval; see the legal status.
What does VIP peptide do?
As a naturally occurring signalling peptide it dilates blood vessels, and an infusion study found it lowered blood pressure in healthy people.[10]
More on VIP
Sources
- 1Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025PMID 39870064Accessed 2 Oct 2026
- 2Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
- 3The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
- 4Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
- 5Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.The journal of sexual medicine · 2025PMID 40192471Accessed 2 Oct 2026
- 6Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024PMID 38510776Accessed 2 Oct 2026
- 7Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures.The American journal of case reports · 2016PMID 27165859Accessed 2 Oct 2026
- 8Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.American journal of respiratory and critical care medicine · 2010PMID 20442436Accessed 2 Oct 2026
- 9Inhalation of vasoactive intestinal peptide in pulmonary hypertension.The European respiratory journal · 2008PMID 18978135Accessed 2 Oct 2026
- 10Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
- 11Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025PMID 41368449Accessed 2 Oct 2026
- 12Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.BJU international · 2008PMID 18485029Accessed 2 Oct 2026
- 13PubMed search: aviptadil[tiab] (30 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (1509 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (70 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: "vasoactive intestinal peptide"[tiab] AND (CIRS[tiab] OR "inflammatory response syndrome"[tiab] OR mycotoxin*[tiab] OR "water-damaged"[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: "vasoactive intestinal peptide"[tiab] AND ("clinical trial"[pt] OR randomized[tiab]) AND (inhal*[tiab] OR intranasal[tiab] OR sarcoid*[tiab] OR "pulmonary hypertension"[tiab] OR ARDS[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: aviptadil[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 20PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (humans[mh]) (94 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.